Dominik Burri

Dominik Burri

Auto-generated profile, based on publicly available information

Dominik Burri

Department of Biomedicine, Bioinformatics Core Facility, University of Basel, 4031 Basel, Switzerland; Swiss Institute of Bioinformatics, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Nature Ecology & Evolution
Verified
Journal Article
Open access
PDF file
RNRobert Noble
Robert Noble
DBDominik Burri
Dominik Burri
CSCécile Le Sueur
Cécile Le Sueur
JLJeanne Lemant
Jeanne Lemant
YVYannick Viossat
Yannick Viossat
NBNiko Beerenwinkel
Niko Beerenwinkel
Characterizing the mode—the way, manner or pattern—of evolution in tumours is important for clinical forecasting and optimizing cancer treatment. Sequencing studies have inferred various modes, including branching, punctuated and neutral evolution, but it is unclear why a particular pattern predominates in any given tumour. Here we propose that tumour architecture is key to explaining the variety of observed genetic patterns. We examine this hypothesis using spatially explicit population genetics models and demonstrate that, within biologically relevant parameter ranges, different spatial structures can generate four tumour evolutionary modes: rapid clonal expansion, progressive diversification, branching evolution and effectively almost neutral evolution. Quantitative indices for describing and classifying these evolutionary modes are presented. Using these indices, we show that our model predictions are consistent with empirical observations for cancer types with corresponding spatial structures. The manner of cell dispersal and the range of cell–cell interactions are found to be essential factors in accurately characterizing, forecasting and controlling tumour evolution.

19 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DHDaniel Ham
Daniel Ham
ABAnastasiya Börsch
Anastasiya Börsch
KCKathrin Chojnowska
Kathrin Chojnowska
SLShuo Lin
Shuo Lin
ALAurel B. Leuchtmann
Aurel B. Leuchtmann
MRMarkus A. Rüegg
Markus A. Rüegg
Preserving skeletal muscle function is essential to maintain life quality at high age. Calorie restriction (CR) potently extends health and lifespan, but is largely unachievable in humans, making “CR mimetics” of great interest. CR targets nutrient-sensing pathways centering on mTORC1. The mTORC1 inhibitor, rapamycin, is considered a potential CR mimetic and is proven to counteract age-related muscle loss. Therefore, we tested whether rapamycin acts via similar mechanisms as CR to slow muscle aging. Here we show that long-term CR and rapamycin unexpectedly display distinct gene expression profiles in geriatric mouse skeletal muscle, despite both benefiting aging muscles. Furthermore, CR improves muscle integrity in mice with nutrient-insensitive, sustained muscle mTORC1 activity and rapamycin provides additive benefits to CR in naturally aging mouse muscles. We conclude that rapamycin and CR exert distinct, compounding effects in aging skeletal muscle, thus opening the possibility of parallel interventions to counteract muscle aging.

28 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LDLaura Ducimetière
Laura Ducimetière
GLGiulia Lucchiari
Giulia Lucchiari
GLGioana Litscher
Gioana Litscher
MNMarc Nater
Marc Nater
LHLaura Heeb
Laura Heeb
STSonia Tugues
Sonia Tugues
Significance: Innate lymphoid cells hold great promise for the treatment of metastases. Development of effective therapies based on these versatile immune cells, however, is hampered by our limited knowledge of their behavior in the metastatic niche. Here, we describe that defense against liver metastasis requires collaboration between two innate lymphocyte subsets, conventional NK cells (cNKs) and tissue-resident type I innate lymphoid cells (trILC1s). We show that different cancers generate their own particular metastatic niche–inducing specific changes in cNKs and trILC1s. Furthermore, we uncover specific cNK subsets that can be manipulated to improve their antimetastatic potential. Our work contributes to understanding how cancer-specific factors and hepatic innate lymphocytes exert mutual influence and how this can be exploited for therapeutic purposes.

14 September 2021 in RNA
Verified
Journal Article
Open access
PDF file
DBDominik Burri
Dominik Burri
MZMihaela Zavolan
Mihaela Zavolan
During pre-mRNA maturation 3′ end processing can occur at different polyadenylation sites in the 3′ untranslated region (3′ UTR) to give rise to transcript isoforms that differ in the length of their 3′ UTRs. Longer 3′ UTRs contain additionalcis-regulatory elements that impact the fate of the transcript and/or of the resulting protein. Extensive alternative polyadenylation (APA) has been observed in cancers, but the mechanisms and roles remain elusive. In particular, it is unclear whether the APA occurs in the malignant cells or in other cell types that infiltrate the tumor. To resolve this, we developed a computational method, called SCUREL, that quantifies changes in 3′ UTR length between groups of cells, including cells of the same type originating from tumor and control tissue. We used this method to study APA in human lung adenocarcinoma (LUAD). SCUREL relies solely on annotated 3′ UTRs and on control systems such as T cell activation, and spermatogenesis gives qualitatively similar results at much greater sensitivity compared to the previously published scAPA method. In the LUAD samples, we find a general trend toward 3′ UTR shortening not only in cancer cells compared to the cell type of origin, but also when comparing other cell types from the tumor vs. the control tissue environment. However, we also find high variability in the individual targets between patients. The findings help in understanding the extent and impact of APA in LUAD, which may support improvements in diagnosis and treatment.

19 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMaria Katsantoni
Maria Katsantoni
FGFoivos Gypas
Foivos Gypas
CHChristina J. Herrmann
Christina J. Herrmann
DBDominik Burri
Dominik Burri
MBMaciej Bak
Maciej Bak
AKAlexander Kanitz
Alexander Kanitz
RNA sequencing (RNA-seq) is a crucial technique for many scientific studies and multiple models, and software packages have been developed for the processing and analysis of such data. Given the plethora of available tools, choosing the most appropriate ones is a time-consuming process that requires an in-depth understanding of the data, as well as of the principles and parameters of each tool. In addition, packages designed for individual tasks are developed in different programming languages and have dependencies of various degrees of complexity, which renders their installation and execution challenging for users with limited computational expertise. The use of workflow languages and execution engines with support for virtualization and encapsulation options such as containers and Conda environments facilitates these tasks considerably. Computational workflows defined in those languages can be reliably shared with the scientific community, enhancing reusability, while improving reproducibility of results by making individual analysis steps more transparent. Here we present ZARP, a general purpose RNA-seq analysis workflow which builds on state-of-the-art software in the field to facilitate the analysis of RNA-seq data sets. ZARP is developed in the Snakemake workflow language using best software development practices. It can run locally or in a cluster environment, generating extensive reports not only of the data but also of the options utilized. It is built using modern technologies with the ultimate goal to reduce the hands-on time for bioinformaticians and non-expert users. ZARP is available under a permissive Open Source license and open to contributions by the scientific community. Contact mihaela.zavolan{at}unibas.ch , alexander.kanitz{at}unibas.ch

5 July 2023 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
PDF file
YMYoungbin Moon
Youngbin Moon
DBDominik Burri
Dominik Burri
MZMihaela Zavolan
Mihaela Zavolan
Alternative polyadenylation is a main driver of transcriptome diversity in mammals, generating transcript isoforms with different 3’ ends via cleavage and polyadenylation at distinct polyadenylation (poly(A)) sites. The regulation of cell type-specific poly(A) site choice is not completely resolved, and requires quantitative poly(A) site usage data across cell types. 3’ end-based single-cell RNA-seq can now be broadly used to obtain such data, enabling the identification and quantification of poly(A) sites with direct experimental support. We propose SCINPAS, a computational method to identify poly(A) sites from scRNA-seq datasets. SCINPAS modifies the read deduplication step to favor the selection of distal reads and extract those with non-templated poly(A) tails. This approach improves the resolution of poly(A) site recovery relative to standard software. SCINPAS identifies poly(A) sites in genic and non-genic regions, providing complementary information relative to other tools. The workflow is modular, and the key read deduplication step is general, enabling the use of SCINPAS in other typical analyses of single cell gene expression. Taken together, we show that SCINPAS is able to identify experimentally-supported, known and novel poly(A) sites from 3’ end-based single-cell RNA sequencing data.